The study will evaluate the oral bioavailability of RX-3117 in humans.
The company will continue the enrollment through the first half of 2012 and expects to release the preliminary in second half of 2012.
RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that inhibits DNA methyltransferase, a cyclin-dependent kinase, and DNA synthesis.
Rexahn president Rick Soni said RX-3117 has demonstrated good safety profile in preclinical studies, providing the compound with potential applications in a range of solid tumors.